Saidi Dalya, Obeidat Marya, Alsotari Shrouq, Ibrahim Abed-Alqader, Al-Buqain Rula, Wehaibi Suha, Alqudah Dana A, Nsairat Hamdi, Alshaer Walhan, Alkilany Alaaldin M
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Cell Therapy Center, The University of Jordan, Amman, 11942, Jordan.
Heliyon. 2024 May 8;10(10):e30743. doi: 10.1016/j.heliyon.2024.e30743. eCollection 2024 May 30.
Anti-nucleolin (NCL) aptamer AS1411 is the first anticancer aptamer tested in clinical trials. Gold nanoparticles (AuNP) have been widely exploited for various biomedical applications due to their unique functional properties. In this study, we evaluated the colloidal stability and targeting capacity of AS1411-funtionalized AuNP (AuNP/NCL-Apt) against MCF-7 breast cancer cell line before and after lyophilization. Trehalose, mannitol, and sucrose at various concentrations were evaluated to determine their cryoprotection effects. Our results indicate that sucrose at 10 % (w/v) exhibits the best cryoprotection effect and minimal AuNP/NCL-Apt aggregation as confirmed by UV-Vis spectroscopy and dynamic light scattering (DLS) measurements. Moreover, the lyophilized AuNP/NCL-Apt at optimized formulation maintained its targeting and cytotoxic functionality against MCF-7 cells as proven by the cellular uptake assays utilizing flow cytometry and confocal laser scanning microscopy (CLSM). Quantitative PCR (qPCR) analysis of nucleolin-target gene expression also confirmed the effectiveness of AuNP/NCL-Apt. This study highlights the importance of selecting the proper type and concentration of cryoprotectant in the typical nanoparticle lyophilization process and contributes to our understanding of the physical and biological properties of functionalized nanoparticles upon lyophilization.
ACS Appl Mater Interfaces. 2015-3-11
Colloids Surf B Biointerfaces. 2022-9
Biomed Pharmacother. 2022-11
Technol Cancer Res Treat. 2025
Technol Cancer Res Treat. 2025
Future Sci OA. 2024-12-31
J Control Release. 2023-2
Chem Commun (Camb). 2022-9-29
Materials (Basel). 2022-5-7
Pharmaceutics. 2022-3-17
Pharmaceutics. 2022-3-17
J Nanobiotechnology. 2022-1-31
Curr Med Chem. 2023